Loading...
Loading...
ARDX| Name | Value |
|---|---|
| Revenues | 34.4M |
| Cost of Revenue | 5.1M |
| Gross Profit | 29.3M |
| Operating Expense | 57.3M |
| Operating I/L | -28.0M |
| Other Income/Expense | 2.3M |
| Interest Income | 0.0M |
| Pretax | -28.5M |
| Income Tax Expense | 0.3M |
| Net Income/Loss | -28.8M |
Ardelyx, Inc. is a biopharmaceutical company specializing in gastrointestinal and cardiorenal medicines. Its lead product candidate, tenapanor, is in Phase III clinical trials for irritable bowel syndrome with constipation and hyperphosphatemia in chronic kidney disease patients on dialysis. The company is also developing RDX013 for hyperkalemia and RDX020 for metabolic acidosis in CKD patients. Ardelyx has partnerships with Kyowa Kirin, Fosun Pharmaceutical, and Knight Therapeutics for the development and commercialization of tenapanor in Japan, China, and Canada respectively.
